Until a sensitive and specific YAP inhibitor is developed and identified for its therapeutic potential in neuroblastoma, alternative methods to exploit targets and signaling pathways downstream of YAP should continue to be explored. This evidence concerns the gene YAP1 and neuroblastoma.